Flow cytometry analysis utilizing Annexin V/PI staining reveals that the incorporation of KS18 reinstated the responsiveness of bortezomib in resistant cells, suggesting that KS18-based therapeutic combinations are efficacious against resistant cells and can re-sensitize multiple myeloma cells to chemotherapy (Figure 5F). This evidence concerns the gene ANXA5 and plasma cell myeloma.